GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noxopharm Ltd (OTCPK:NOXOF) » Definitions » Equity-to-Asset

Noxopharm (Noxopharm) Equity-to-Asset : 0.92 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Noxopharm Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Noxopharm's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $4.40 Mil. Noxopharm's Total Assets for the quarter that ended in Dec. 2023 was $4.79 Mil.

The historical rank and industry rank for Noxopharm's Equity-to-Asset or its related term are showing as below:

NOXOF' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.02   Med: 0.85   Max: 0.97
Current: 0.92

During the past 7 years, the highest Equity to Asset Ratio of Noxopharm was 0.97. The lowest was -1.02. And the median was 0.85.

NOXOF's Equity-to-Asset is ranked better than
89.84% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs NOXOF: 0.92

Noxopharm Equity-to-Asset Historical Data

The historical data trend for Noxopharm's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noxopharm Equity-to-Asset Chart

Noxopharm Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Equity-to-Asset
Get a 7-Day Free Trial -0.02 0.64 0.85 0.91 0.90

Noxopharm Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.93 0.91 0.85 0.90 0.92

Competitive Comparison of Noxopharm's Equity-to-Asset

For the Biotechnology subindustry, Noxopharm's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Noxopharm's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Noxopharm's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Noxopharm's Equity-to-Asset falls into.



Noxopharm Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Noxopharm's Equity to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Equity to Asset (A: Jun. 2023 )=Total Stockholders Equity/Total Assets
=6.089/6.797
=

Noxopharm's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=4.401/4.79
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Noxopharm  (OTCPK:NOXOF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Noxopharm Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Noxopharm's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Noxopharm (Noxopharm) Business Description

Traded in Other Exchanges
Address
60 Linksley Ave, Glenhaven, NSW, AUS, 2156
Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.

Noxopharm (Noxopharm) Headlines

From GuruFocus

Noxopharm's Veyonda to Begin First-Line Sarcoma Treatment Testing

By Business Wire Business Wire 05-11-2021

FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment

By Business Wire Business Wire 03-29-2022

Noxopharm Announces Pilot Study With Bristol Myers Squibb's Product

By Business Wire Business Wire 11-12-2020

Clinical Data Shows Noxopharm's Veyonda� May Prevent Cytokine Storm

By Business Wire Business Wire 04-27-2021

Independent Discovery Validates Noxopharm's DARRT Cancer Therapy

By Business Wire Business Wire 12-03-2020

Noxopharm Announces DARRT-2 Clinical Trial in U.S.

By Business Wire Business Wire 11-09-2021

Noxopharm Subsidiary Announces Important Drug Discovery

By PRNewswire PRNewswire 09-24-2018